MitoKor data retracted

Although therapeutic or diagnostic strategies pursued by biotech companies generally are proprietary, academic research still can affect a company's plans. In January, two academic papers published in the Proceedings of the National Academy of Sciences contradicted previously published results from MitoKor Inc., and the company now has retracted its results.

MitoKor now also believes that the polymorphisms are in fact in nuclear mitochondrial-like DNA (numtDNA) fragments...